

Dementia Antipsychotic Prescribing Guide

General Guidelines:

1. Rule out reversible causes prior to using a drug.
2. Try non-drug management strategies first.
3. Clearly document treatment targets (symptoms) before and after a treatment strategy is tried.
4. Justify use of an antipsychotic. The treatment target symptom must present a **danger to the person or others**, or cause the patient to experience one of the following:
 - inconsolable or persistent distress
 - a significant decline in function
 - substantial difficulty receiving needed care
5. See Guidance for Special Populations, if the patient has frontotemporal dementia, Parkinson's disease, Lewy body dementia, renal impairment, or hepatic impairment.
6. Consider the impact of side effects on comorbidities when choosing a drug, and start with a low dose.
7. If the drug doesn't help, stop it (use appropriate tapering).

Appropriate antipsychotic treatment targets:^{*}

- Aggressive behavior (especially physical)
- Hallucinations (if distressing)
- Delusions (note: memory problems are often mistaken for delusions, e.g. thinks people are stealing lost items)
- Severe distress as described above in #4 General Guidelines

Inappropriate antipsychotic treatment targets:^{*}

- Wandering
- Unsociability
- Poor self-care
- Restlessness
- Uncooperativeness without aggressive behavior
- Inattention or indifference to surroundings
- Verbal expressions or behaviors that do not represent a danger to the resident or others
- Nervousness
- Fidgeting
- Mild anxiety
- Impaired memory

*According to CMS regulations for long-term care facilities

Antipsychotic Efficacy

Evidence supports modest symptom improvements with **aripiprazole**, **haloperidol***, **olanzapine**, **quetiapine**, and **risperidone**, but not with use of other antipsychotics in dementia. All antipsychotics appear to increase risk of death. The table below summarizes the strength of evidence supporting the efficacy of each **atypical antipsychotic** for different symptom domains.

	Aripiprazole	Olanzapine	Quetiapine	Risperidone
Dementia overall	++	+	+	++
Dementia psychosis	+	+ / -	+ / -	++
Dementia agitation	+	++	+ / -	++

++ = moderate or high evidence of efficacy

+ = low or very low evidence of efficacy

+ / - = mixed results

*Haloperidol has shown efficacy for aggression in randomized trials

Adverse Effects Comparison Table

Drug <i>Brand Name</i> (daily dose range)	Aripiprazole Abilify (2-10 mg)	Haloperidol Haldol (0.25-2 mg)	Olanzapine Zyprexa (2.5-7.5 mg)	Quetiapine Seroquel (12.5-150 mg)	Risperidone Risperdal (0.25-2 mg)
<i>Movement Side Effects¹</i>	■ ■	■ ■ ■ ■	■ ■ ■ ■	■ ■ ■ ■	■ ■ ■ ■
<i>Central Nervous System</i>					
Sedation	■ ■	■ ■ ■ ■	■ ■ ■ ■	■ ■ ■ ■	■ ■ ■ ■
Confusion, delirium, cognitive worsening	■	0	■ ■ ■ ■	■ ■ ■ ■	■ ■ ■ ■
Worsening psychotic symptoms	0	0	0	0	0
<i>Cardiovascular/Metabolic</i>					
Orthostatic hypotension	■ ?	■ ■	■ ■ ■ ■	■ ■ ■ ■	■ ■ ■ ■
Edema	■ ?	0	■ ■ ■ ■	■ ■ ■ ■	■ ■ ■ ■
Weight gain/glucose ↑	0	■ ?	■ ■ ■ ■	■ ■ ■ ■	■ ■ ■ ■
Triglyceride ↑	0	0	■ ■ ■ ■	■ ■ ■ ■	■ ■ ■ ■
Urinary incontinence, UTI	■ ■ ■ ■	■ ■ ■ ■	■ ■ ■ ■	■ ■ ■ ■	■ ■ ■ ■

■ = more boxes indicates greater risk. Colors are darker with increasing risk.

■ ? = evidence poor in dementia, but evidence in other conditions indicates some risk

0 = no clear evidence that the drug causes this side effect in a clinically important way, or very rarely

¹ Movement side effects = Parkinsonism, akathisia (restlessness), dystonia, tardive dyskinesia